Program
NVX-COV2705
Its studies are mostly in COVID-19, led by 2 companies.
Furthest: phase 4, since Jul 17, 20252 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novavax | 10 open or running | phase 4since Jul 17, 2025 | Jul 17, 2025 | none ahead |
| Sanofi | 10 open or running | phase 3since Jul 14, 2025 | Jul 14, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 14, 2025First study: phase 3 study in COVID-19New to SanofiSanofi · NCT07079670 · 676 enrolled · United States
- Jul 17, 2025Novavax’s first study: phase 4 study in COVID-19New to NovavaxNovavax · NCT07086222 · 6,500 enrolled · United States
- Oct 23, 2026Phase 4 study terminatedStudy stoppedNCT07086222 · “The study was terminated early due to low COVID-19 incidence and high population immunity, limiting meaningful vaccine efficacy assessmen…”
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07086222COVID-19 · United States | 4 | Terminated | Novavax | Oct 9, 2026 | 6,500 |
| NCT07079670COVID-19 · United States | 3 | Completed | Sanofi | Jan 12, 2026 | 676 |
How it is read
Names in the registry
- “NVX-CoV2705”, 2 entries
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.